Clinical Trial Results:
Interventional clinical trial to assess efficacy and safety of the extemporaneous combination of Zofenopril calcium and amlodipine in grade 1-2 hypertensive patients versus each monotherapy
Summary
|
|
EudraCT number |
2021-000745-40 |
Trial protocol |
IT |
Global end of trial date |
28 Apr 2022
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
14 May 2023
|
First version publication date |
14 May 2023
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
MEIN/20/ZoAm-Hyp/001
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT05279807 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Menarini International Operation Luxembourg SA
|
||
Sponsor organisation address |
1, Avenue de la Gare, Luxembourg, Luxembourg, L-1611
|
||
Public contact |
Medical Affairs & Clinical Operation Director Paolo Fabrizzi, Menarini , +39 055568091, pfabrizzi@menarini.it
|
||
Scientific contact |
Medical Affairs & Clinical Operation Director Paolo Fabrizzi, Menarini , +39 055568091, pfabrizzi@menarini.it
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
24 Oct 2022
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
28 Apr 2022
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
28 Apr 2022
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
Primary Objective: To assess the anti-hypertensive efficacy of the extemporaneous combination of ZOF 30 mg with AML 5 mg or AML 10 mg in lowering the sitting diastolic BP between Visit 2 (Week 0) and Visit 4 (Week 8) in patients with uncontrolled BP previously treated with ZOF (30 mg) or AML (5 mg) monotherapies for at least 4 weeks.
|
||
Protection of trial subjects |
The study was conducted in compliance with International Council for Harmonisation (ICH) Good Clinical
Practices (GCP), including the archiving of essential documents as well as the ethical principles of the
Declaration of Helsinki.
|
||
Background therapy |
No Background Therapy | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
15 Oct 2021
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Hungary: 270
|
||
Country: Number of subjects enrolled |
Russian Federation: 7
|
||
Worldwide total number of subjects |
277
|
||
EEA total number of subjects |
270
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
277
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||
Recruitment
|
|||||||||||||||||||
Recruitment details |
Study started on 15 October 2021 and terminated on 28 April 2022 290 patients were screened for the study. 277 patients entered the run-in period and were assigned for monotherapy to Amlodipine (AML) 5 mg or Zofenopril (ZOF) 30 mg. All 271 completed patients in monotherapy were assigned to combination therapy and 269 completed the study. | ||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||
Screening details |
290, Grade 1-2 hypertensive patients with blood pressure [BP] ranging from ≥ 140 / 90 mmHg to ≤ 179 / 109 mmHg) in treatment with any ACE-I or CCBs, including ZOF 30 mg or AML 5 mg (only dosage allowed) for at least one month prior to Visit 1 (Week -4), were screened for eligibility. | ||||||||||||||||||
Period 1
|
|||||||||||||||||||
Period 1 title |
Run-in Period
|
||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||
Allocation method |
Non-randomised - controlled
|
||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||
Blinding implementation details |
Open-label study, not blinded
|
||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
Zofenopril 30mg | ||||||||||||||||||
Arm description |
Eligible patients entered a 4 week run-in period on the same day of the screening visit. Patients previously receiving ZOF 30 mg continued the same treatment, patients receiving any other ACE-i were switched to ZOF 30 mg | ||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||
Investigational medicinal product name |
Zofenopril 30mg
|
||||||||||||||||||
Investigational medicinal product code |
Zofenopril Calcium
|
||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Film-coated tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
1 tablet of study drug administered with a glass of water once daily
|
||||||||||||||||||
Arm title
|
Amlodipine 5mg | ||||||||||||||||||
Arm description |
Eligible patients entered a 4 week run-in period on the same day of the screening visit. Patients previously receiving AML 5 mg continued the same treatment, while patients receiving any other CCBs were switched to AML 5 mg | ||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||
Investigational medicinal product name |
Amlodipine 5mg
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
1 tablet of study drug was administered with a glass of water once daily
|
||||||||||||||||||
|
|||||||||||||||||||
Period 2
|
|||||||||||||||||||
Period 2 title |
Assessment
|
||||||||||||||||||
Is this the baseline period? |
Yes [1] | ||||||||||||||||||
Allocation method |
Non-randomised - controlled
|
||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||
Arms
|
|||||||||||||||||||
Arm title
|
Combination Therapy Zofenopril 30mg/Amlodipine 5mg or 10mg | ||||||||||||||||||
Arm description |
Patients having uncontrolled BP (SBP/DBP > 130 / 80 mmHg) at Visit 2 (Week 0), were assigned to the extemporaneous combination of ZOF 30 mg and AML 5 mg. After 4 Weeks ± 2 days the BP was assessed again (Visit 3, Week 4): controlled patients (SBP/DBP ≤ 130 / 80 mmHg) continued the same extemporaneous combination, while uncontrolled (SBP/DBP > 130 / 80 mmHg) patients were up-titrated to extemporaneous combination of ZOF/AML 30 mg / 10 mg for another 4 weeks ± 2 days (Visit 4, Week 8). At Visit 2 (Week 0) and Visit 3 (Week 4) patients with SBP/DBP value classified as Grade 3 (SBP ≥ 180 or DBP ≥ 110 mmHg) hypertension were withdrawn from the study. To correctly evaluate additional effect of the combination therapy, the number of patients with uncontrolled BP on AML or ZOF monotherapy needed to be balanced at Week 0. Weekly evaluations were performed to maintain a 1:1 ratio during the assessment period 2. Corrective measures were initiated in case of 5% differences between the two groups. | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
Zofenopril 30mg
|
||||||||||||||||||
Investigational medicinal product code |
Zofenopril Calcium
|
||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Film-coated tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
1 tablet of study drug administered with a glass of water once daily
|
||||||||||||||||||
Investigational medicinal product name |
Amlodipine 5/10 mg
|
||||||||||||||||||
Investigational medicinal product code |
Amlodipine besylate
|
||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
1 tablet of study drug was administered with a glass of water once daily.
|
||||||||||||||||||
Notes [1] - Period 1 is not the baseline period. It is expected that period 1 will be the baseline period. Justification: Period 1 is the Run-in period. The objective of the study is to evaluate the effectiveness and safety of the combination therapy (Zofenopril/Amlodipine) versus the monotherapy. Hence the baseline period starts on Period 2, with the assessment of blood pressure after the run-in period and the intake of the combination therapy. |
|||||||||||||||||||
|
|||||||||||||||||||
Notes [2] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same. Justification: 277 patients are enrolled patients that are included in the study and start the Run-in period (Period 1). Period 1 is not the baseline period. The baseline period is Period 2 (Assessment) where patients start to take the combination therapy ZOF 30 mg/AML 5 mg /AML 10 mg [3] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period. Justification: After the Run-in Period, Patients with controlled BP (sitting SBP / DBP ≤ 130/80 mmHg) at Week 0 (Visit 2), patients with uncontrolled BP (sitting SBP / DBP > 130/80 mmHg) whose adherence to the treatment was not included from 80% to 120%, or patients who could not tolerate one of the mono therapies were discontinued from the study and excluded from the Assessment Period (3 patients in total) |
|
|||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||
Reporting group title |
Assessment
|
||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Zofenopril 30mg
|
||
Reporting group description |
Eligible patients entered a 4 week run-in period on the same day of the screening visit. Patients previously receiving ZOF 30 mg continued the same treatment, patients receiving any other ACE-i were switched to ZOF 30 mg | ||
Reporting group title |
Amlodipine 5mg
|
||
Reporting group description |
Eligible patients entered a 4 week run-in period on the same day of the screening visit. Patients previously receiving AML 5 mg continued the same treatment, while patients receiving any other CCBs were switched to AML 5 mg | ||
Reporting group title |
Combination Therapy Zofenopril 30mg/Amlodipine 5mg or 10mg
|
||
Reporting group description |
Patients having uncontrolled BP (SBP/DBP > 130 / 80 mmHg) at Visit 2 (Week 0), were assigned to the extemporaneous combination of ZOF 30 mg and AML 5 mg. After 4 Weeks ± 2 days the BP was assessed again (Visit 3, Week 4): controlled patients (SBP/DBP ≤ 130 / 80 mmHg) continued the same extemporaneous combination, while uncontrolled (SBP/DBP > 130 / 80 mmHg) patients were up-titrated to extemporaneous combination of ZOF/AML 30 mg / 10 mg for another 4 weeks ± 2 days (Visit 4, Week 8). At Visit 2 (Week 0) and Visit 3 (Week 4) patients with SBP/DBP value classified as Grade 3 (SBP ≥ 180 or DBP ≥ 110 mmHg) hypertension were withdrawn from the study. To correctly evaluate additional effect of the combination therapy, the number of patients with uncontrolled BP on AML or ZOF monotherapy needed to be balanced at Week 0. Weekly evaluations were performed to maintain a 1:1 ratio during the assessment period 2. Corrective measures were initiated in case of 5% differences between the two groups. | ||
Subject analysis set title |
Efficacy Population
|
||
Subject analysis set type |
Intention-to-treat | ||
Subject analysis set description |
All study participants who signed informed consent , met all screening criteria, were enrolled and received at least one dose of the assigned treatment during run-in period, completed the 4-week run-in period and met criteria at Visit 2 (Week 0) [uncontrolled BP (sitting SBP/DBP > 130 / 80 mmHg)], tolerated treatment, had treatment adherence between 80 – 120 % and had at least one available post baseline primary efficacy assessment [(from Visit 3 (Week 4) or Visit 4 (Week 8)].
|
|
|||||||||||||
End point title |
Change in mean sitting DBP | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
8 weeks of combination therapy treatment. From study Visit 2 (Week 0) to study Visit 4 (Week 8)
|
||||||||||||
|
|||||||||||||
Notes [1] - Values collected here are DBP measurement at the end of the study [2] - Only 271 patients have valid DBP measurement at baseline. Values collected here are baseline ones |
|||||||||||||
Statistical analysis title |
DBP at Visit 2 (Week 0) vs Visit 4 (Week 8) | ||||||||||||
Statistical analysis description |
Change from Baseline in the Diastolic Blood Pressure (DBP).
|
||||||||||||
Comparison groups |
Combination Therapy Zofenopril 30mg/Amlodipine 5mg or 10mg v Efficacy Population
|
||||||||||||
Number of subjects included in analysis |
540
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.001 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Confidence interval |
|
|||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
From Informed Consent signed to final visit
|
||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||
Dictionary version |
24
|
||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||
Reporting group title |
Combination Therapy Zofenopril 30mg/Amlodipina 5mg or 10mg
|
||||||||||||||||||||||||||||||||||||
Reporting group description |
Patients having uncontrolled BP (SBP/DBP > 130 / 80 mmHg) at Visit 2 (Week 0), were assigned to the extemporaneous combination of ZOF 30 mg and AML 5 mg. After 4 Weeks ± 2 days the BP was assessed again (Visit 3, Week 4): controlled patients (SBP/DBP ≤ 130 / 80 mmHg) continued the same extemporaneous combination, while uncontrolled (SBP/DBP > 130 / 80 mmHg) patients were up-titrated to extemporaneous combination of ZOF/AML 30 mg / 10 mg for another 4 weeks ± 2 days (Visit 4, Week 8). At Visit 2 (Week 0) and Visit 3 (Week 4) patients with SBP/DBP value classified as Grade 3 (SBP ≥ 180 or DBP ≥ 110 mmHg) hypertension were withdrawn from the study. To correctly evaluate additional effect of the combination therapy, the number of patients with uncontrolled BP on AML or ZOF monotherapy needed to be balanced at Week 0. Weekly evaluations were performed to maintain a 1:1 ratio during the assessment period. Corrective measures were initiated in case of 5% differences between the two groups. | ||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 1% | |||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
Note that due to technical limits in the portal the statistical analysis reports 540 patients included in the analysis and not 271 as they effectively are. 540 are indeed the 271 data collected before and the 269 after combined therapy intake |